Mentions
Extended reach
Total likes
Video views
AI synopsis
Participants show moderate interest and engagement, referencing the study’s design, funding, and protocol publication through phrases like 'fascinated to know your thoughts' and 'the full trial protocol published,' indicating curiosity and support for transparency without deeply critiquing or analyzing the findings. The tone is mostly neutral and supportive, emphasizing community involvement and current research activity, but lacking strong opinions or calls to action.
The discussions generally acknowledge the study but do not show strong consensus for or against its conclusions.
Participants express some curiosity about the trial, funding, and design, but overall interest remains moderate.
Comments include basic acknowledgments and questions, indicating some engagement but limited in-depth analysis.
The discussions highlight awareness and support for the trial but do not indicate a perceived high impact on the field or practice.
The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particular @mkaeberlein (co-author) for assistance with the overall trial design (exciting update about study recruitment coming soon) https://t.co/fNaQmhFgSb
The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
A single-center, double-blind, randomized, placebo-controlled, two-arm study to evaluate the safety and efficacy of once-weekly sirolimus (rapamycin) on muscle strength and endurance in older adults following a 13-week exercise program @BradStanfieldMD @mkaeberlein @BruceArroll https://t.co/0fZxbtucQR
Here's the full trial protocol, published in a peer-reviewed journal: https://t.co/fNaQmhFgSb
@OraBiomedical @KristerKauppi A very recent study on exercise and rapamycin. https://t.co/S10O7dshQy https://t.co/U8z8rUnH5a
@precuneanplexus @nearcyan Well, studies are being done on older people to see if rapamycin helps improve muscle strength. In old age there is thought to be overactivation of mtor, and not enough proper rest. See this planned one: https://t.co/IQeReT2Z5V
This video explores the science behind longevity medicine, including gene control of aging, clinical trials, and societal impacts. It discusses how emerging therapies could influence aging and health in humans, based on…
Rapamycin might be the most powerful longevity drug ever discovered, slowing aging by tricking cells into thinking they are fasting. This video explains how rapamycin works, the findings from ITP studies, and its…
@spirit_raccoon @annesmithmcc @ZacharyGrinDPT @bmj_latest Trial underway here: https://t.co/mZuYtZ6SXv
@PeterAttiaMD, would be fascinated to know your thoughts on this rapamycin RCT - thoughts on the design and outcome selection? https://t.co/Hskbnp6oy3
RT @vita_dao: The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
@precuneanplexus @nearcyan Well, studies are being done on older people to see if rapamycin helps improve muscle strength. In old age there is thought to be overactivation of mtor, and not enough proper rest. See this planned one: https://t.co/IQeReT2Z5V
@OraBiomedical @KristerKauppi A very recent study on exercise and rapamycin. https://t.co/S10O7dshQy https://t.co/U8z8rUnH5a
RT @BradStanfieldMD: Here's the full trial protocol, published in a peer-reviewed journal: https://t.co/fNaQmhFgSb
Here's the full trial protocol, published in a peer-reviewed journal: https://t.co/fNaQmhFgSb
RT @vita_dao: The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
RT @vita_dao: The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
RT @vita_dao: The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
RT @vita_dao: The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
RT @vita_dao: The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
The VitaDAO community helped fund the Rapamycin & Exercise clinical trial.
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @agingdoc1: A single-center, double-blind, randomized, placebo-controlled, two-arm study to evaluate the safety and efficacy of once-wee…
RT @agingdoc1: A single-center, double-blind, randomized, placebo-controlled, two-arm study to evaluate the safety and efficacy of once-wee…
A single-center, double-blind, randomized, placebo-controlled, two-arm study to evaluate the safety and efficacy of once-weekly sirolimus (rapamycin) on muscle strength and endurance in older adults following a 13-week exercise program @BradStanfieldMD @mkaeberlein @BruceArroll https://t.co/0fZxbtucQR
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
RT @BradStanfieldMD: The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particul…
The Rapamycin & Exercise clinical trial protocol is now published! Thank you to all for your support, and in particular @mkaeberlein (co-author) for assistance with the overall trial design (exciting update about study recruitment coming soon) https://t.co/fNaQmhFgSb
DS
V
A
B
Z
MR
JG
JB
CA
LI
AD
DA
AS
死
MS
T
LJ
D
AT
MK
MU
RP